Home » Topics » BioWorld Science

BioWorld Science
RSS

Regeneron provides updates on phase III development program of Libtayo in NSCLC

Nov. 6, 2019

Initiation of phase Ib study of mavorixafor in severe congenital neutropenia

Nov. 6, 2019

Further interim data presented from phase Ib study of EDP-1815 in patients with psoriasis

Nov. 6, 2019

eFFECTOR Therapeutics initiates early clinical study of zotatifin in advanced solid tumors

Nov. 6, 2019

Cartesian initiates phase I/II study of its lead CAR-T candidate, Descartes-08

Nov. 6, 2019

HLX-11 receives IND application acceptance notification from NMPA

Nov. 6, 2019

Tau spreads quickly but kills slowly

Nov. 6, 2019

PARP degradation joins trapping, inhibition

Nov. 6, 2019

FDA approves influenza vaccine Fluzone High-Dose Quadrivalent

Nov. 5, 2019

Halozyme Therapeutics to halt development of PEGPH20 following phase III results

Nov. 5, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 7, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.